Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to establish the pharmacokinetic parameters of cherry juice concentrate and identify its potential to alter inflammatory markers in gout patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tart cherry concentrate 60 mL | Active Comparator | Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group. |
|
| Tart cherry concentrate 120 mL | Active Comparator | Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tart cherry extract 60 mL | Dietary Supplement | Subjects will receive a single 60 mL oral dose of tart cherry extract. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Highly sensitive C-reactive protein (hs-CRP) | Reduction in hs-CRP | Maximal change in hs-CRP from baseline through study completion (during the 12 hours after a dose) |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the curve (AUC) | The area under the plasma anthocyanin concentration-time curve | Through study completion (during the 12 hours after a dose) |
| Change in inflammatory marker expression |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Naomi Schlesinger, MD | Robert Wood Johnson Medical School/ Rutgers RWJMS Gout Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Jun 23, 2021 | Jan 5, 2023 | ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D006073 | Gout |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D000070657 | Crystal Arthropathies |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tart cherry extract 120 mL | Dietary Supplement | Subjects will receive a single 120 mL oral dose of tart cherry extract. |
|
Fold change in mRNA expression of Nrf2
| Through study completion (during the 12 hours after a dose) |
| Peak plasma concentration (Cmax) | Peak plasma concentration of anthocyanins | Through study completion (during the 12 hours after a dose) |
| Time to peak plasma concentration (Tmax) | Time to achieve peak plasma anthocyanin concentration | Through study completion (during the 12 hours after a dose) |
| Half-life (t1/2) | Plasma anthocyanin half-life | Through study completion (during the 12 hours after a dose) |
| D012216 |
| Rheumatic Diseases |
| D011686 | Purine-Pyrimidine Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |